A Phase 3 interventional study of XL184 and Placebo in Thyroid Cancer, sponsored by Exelixis. Completed at 114 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-20.
Sponsored by Exelixis · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing cabozantinib in Thyroid Neoplasms — 1 open to participants now, 4 under way, 1 of them phase 3. cabozantinib · Thyroid Neoplasms.
Among the 10 studies testing cabozantinib in Thyroid Neoplasms, this one is the 2nd largest by enrollment, is the only one that started in 2008, is one of 2 in phase 3, and was the 2nd registered.
785 studies on the registry are indexed under Thyroid Neoplasms; 204 are open to participants now.
Browse Thyroid Neoplasms studies →1 of the 10 studies testing cabozantinib in Thyroid Neoplasms is open now, in 1 country. Recruiting first, the newest first:
Fujian Medical University · Sites in China
Ages 18–80
By country, each count listing its studies:
cabozantinib: first FDA approval 2012 (COMETRIQ), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 152 Thyroid Neoplasms studies recruiting now, 96 (63%) set no upper age limit and 27 (18%) stop at 75 or younger; 37 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, cabozantinib is the treatment under test here. Read study by study →
10 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 330 is above the median of 54 across 520 interventional studies indexed under Thyroid Neoplasms.
Median enrollment 64 across the 10 interventional studies. Of the 5 that completed or were terminated, 4 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 10 have an industry lead sponsor. The 5 most frequent:
Exelixis is the lead sponsor of 57 studies on the registry; 11 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Exelixis has 4 studies filed under Thyroid Neoplasms — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing cabozantinib in Thyroid Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this research study is to evaluate the progression-free survival (PFS) with XL184 as compared with placebo (an inactive substance) in subjects with unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC). Subjects will be randomized to receive XL184 or placebo in a 2:1 ratio. XL184 is an investigational drug that inhibits VEGFR2, MET and RET, kinases implicated in tumor formation, growth and migration.
The Clinical Steering Committee for this study, comprised of study doctors who specialize in medullary thyroid cancer, has provided guidance regarding the design of the study. The committee includes: Douglas Ball, MD, Barry Nelkin, PhD, Martin Schlumberger, MD and Steven Sherman, MD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: XL184
Drug: Placebo
Gelatin capsules supplied in 25-mg and 100-mg strengths administered orally daily
Gelatin capsules color and size-matched to XL184 capsules administered orally daily
Progression-Free Survival (PFS)
The duration of Progression-Free Survival (PFS) using progression events as determined by Independent Review Committee (IRC) per mRECIST, or death due to any cause. The analysis was conducted after at least 315 subjects were randomized and at least 138 events were observed.
Time frame: Treatment period consisted of 4-week cycles with radiologic tumor assessment every 12 weeks from date of randomization until date of first documented PD or date of death from any cause, whichever came first, assessed up to 34 months.
Overall Survival (OS) With XL184 Compared With Placebo
Duration of Overall Survival (OS) from the time of randomization to death due to any cause. A Kaplan-Meier analysis was performed to estimate the median.
Time frame: The pre-specified interim analysis of Overall Survival (OS) was assessed at 44% of required events. Includes data up to 15June2011. As of this date, the number of deaths required to conduct the primary analysis had not been reached.
Objective Response Rate (ORR)
The proportion of subjects with a best overall response (BOR) of confirmed complete response (CR) or partial response (PR) as determined by the Independent Review Committee (IRC.) Per Response Evaluation Criteria in Solid Tumor Criteria (mRECIST v1.0) for target lesions and assessed by MRI or CT: Complete Response (CR) disappearance of all target lesions; Partial Response (PR) ≥ 30% decrease in the sum of the longest diameter of target lesions; Progressive Disease (PD) ≥ 20% increase in the sum of the longest diameter of target lesions. Overall Response Rate: ORR=CR +PR
Time frame: Assessed at the same time as primary analysis of Progression Free Survival (PFS) data. Assessed at baseline and every 12 weeks until Progressive Disease (PD) up to 34 months.
Duration of Objective Response (OR): Independent Radiology Committee (IRC) Determined
For those subjects with Independent Radiology Committee (IRC) determined Objective Response Rate (ORR), the amount of time from documentation of Objective Response (OR) until Progressive Disease (PD) by mRECIST or death due to any cause.
Time frame: From time of first documentation of Objective Response (OR), confirmed at a later visit ≥28 days later as Progressive Disease (PD) as defined by mRECIST or death due to any cause, assessed up to 34 months.
Biochemical Response Calcitonin (CTN) %
For each on-treatment tumor marker assessment from each subject, the biochemical response of CTN was determined based on percent increase or decrease from baseline. Best biochemical response over course of treatment was determined from evaluation of subject's time point response data. Biochemical response criteria: Complete Response (CR) - decrease in tumor marker into normal range from baseline value; Partial Response (PR) - decrease of \>50% from baseline value when baseline value is above normal range; Stable Disease (SD) - no more than a 50% increase and no more than a 50% decrease from baseline value above normal range; Progressive Disease (PD) - increase of \>50% from baseline value when baseline value is above normal range / or increase from low or normal range at baseline to above normal range; Not Evaluable (NE) - missing baseline value / or baseline value is not elevated and response is not PD / or response can not be determined due to change in assay format.
Time frame: Serum tumor markers CTN evaluated from blood samples collected at screening and every 12 weeks (±5 days from randomization) until date of first documented progression or date of death from any cause, whichever came first, assessed for up to 34 months.
Biochemical Response Carcinoembryonic Antigen (CEA) %
For each on-treatment tumor marker assessment from each subject, the biochemical response of CEA was determined based on percent increase or decrease from baseline. Best biochemical response over the course of treatment was determined from evaluation of each subject's time point response data. Biochemical response: Complete Response (CR)- Decrease in tumor marker into normal range from baseline value; Partial Response (PR)- Decrease of \>50% from baseline value when baseline value is above normal range; Stable Disease (SD)- No more than a 50% increase and no more than a 50% decrease from baseline value above normal range; Progressive Disease (PD)- Increase of \>50% from baseline value when baseline value is above normal range / or increase from low or normal range at baseline to above normal range; Not Evaluable (NE)- Missing baseline value / or baseline value is not elevated and response is not Progressive Disease (PD) / or response can not be determined due to change in assay format.
Time frame: Serum tumor markers CEA evaluated from blood samples collected at screening and every 12 weeks (± 5 days from randomization) until date of first documented progression or date of death from any cause, whichever came first, assessed for up to 34 months.
First patient enrolled 10 September 2008, last patient enrolled 27 February 2011. Data cut off date 15 June 2011.
| Milestone | XL184 (Cabozantinib) | Placebo |
|---|---|---|
| Started | 219 | 111 |
| Completed | 98 | 15 |
| Not completed | 121 | 96 |
| Withdrew: Adverse event | 35 | 9 |
| Withdrew: Death | 11 | 5 |
| Withdrew: Physician decision | 2 | 0 |
| Withdrew: Did not receive drug | 5 | 2 |
| Withdrew: Disease progression per pi | 58 | 67 |
| Withdrew: Data unavailable | 1 | 0 |
| Withdrew: Withdrawal by subject | 9 | 13 |
The duration of Progression-Free Survival (PFS) using progression events as determined by Independent Review Committee (IRC) per mRECIST, or death due to any cause. The analysis was conducted after at least 315 subjects were randomized and at least 138 events were observed.
| months | XL184 (Cabozantinib) | Placebo |
|---|---|---|
| Progression-Free Survival (PFS) | 11.2 (9.3 to 13.7) | 4.0 (3.0 to 5.4) |
Duration of Overall Survival (OS) from the time of randomization to death due to any cause. A Kaplan-Meier analysis was performed to estimate the median.
| months | XL184 (Cabozantinib) | Placebo |
|---|---|---|
| Overall Survival (OS) With XL184 Compared With Placebo | 21.1 (16.59 to 28.52) | NA (17.41 to NA) |
The proportion of subjects with a best overall response (BOR) of confirmed complete response (CR) or partial response (PR) as determined by the Independent Review Committee (IRC.) Per Response Evaluation Criteria in Solid Tumor Criteria (mRECIST v1.0) for target lesions and assessed by MRI or CT: Complete Response (CR) disappearance of all target lesions; Partial Response (PR) ≥ 30% decrease in the sum of the longest diameter of target lesions; Progressive Disease (PD) ≥ 20% increase in the sum of the longest diameter of target lesions. Overall Response Rate: ORR=CR +PR
| % of participants | XL184 (Cabozantinib) | Placebo |
|---|---|---|
| Objective Response Rate (ORR) | 28 (21.9 to 34.5) | 0 (0 to 0) |
For those subjects with Independent Radiology Committee (IRC) determined Objective Response Rate (ORR), the amount of time from documentation of Objective Response (OR) until Progressive Disease (PD) by mRECIST or death due to any cause.
| months | XL184 (Cabozantinib) | Placebo |
|---|---|---|
| Duration of Objective Response (OR): Independent Radiology Committee (IRC) Determined | 14.6 (11.1 to 17.5) | — |
For each on-treatment tumor marker assessment from each subject, the biochemical response of CTN was determined based on percent increase or decrease from baseline. Best biochemical response over course of treatment was determined from evaluation of subject's time point response data. Biochemical response criteria: Complete Response (CR) - decrease in tumor marker into normal range from baseline value; Partial Response (PR) - decrease of \>50% from baseline value when baseline value is above normal range; Stable Disease (SD) - no more than a 50% increase and no more than a 50% decrease from baseline value above normal range; Progressive Disease (PD) - increase of \>50% from baseline value when baseline value is above normal range / or increase from low or normal range at baseline to above normal range; Not Evaluable (NE) - missing baseline value / or baseline value is not elevated and response is not PD / or response can not be determined due to change in assay format.
| % participants | XL184 (Cabozantinib) | Placebo |
|---|---|---|
| Biochemical Response Calcitonin (CTN) % | 22.6 ± 60.71 | 0.9 ± 115.4 |
For each on-treatment tumor marker assessment from each subject, the biochemical response of CEA was determined based on percent increase or decrease from baseline. Best biochemical response over the course of treatment was determined from evaluation of each subject's time point response data. Biochemical response: Complete Response (CR)- Decrease in tumor marker into normal range from baseline value; Partial Response (PR)- Decrease of \>50% from baseline value when baseline value is above normal range; Stable Disease (SD)- No more than a 50% increase and no more than a 50% decrease from baseline value above normal range; Progressive Disease (PD)- Increase of \>50% from baseline value when baseline value is above normal range / or increase from low or normal range at baseline to above normal range; Not Evaluable (NE)- Missing baseline value / or baseline value is not elevated and response is not Progressive Disease (PD) / or response can not be determined due to change in assay format.
| % of participants | XL184 (Cabozantinib) | Placebo |
|---|---|---|
| Biochemical Response Carcinoembryonic Antigen (CEA) % | 21.6 ± 58.21 | 0.9 ± 182.6 |
Collected over From baseline at regular intervals through to the date of the primary analysis. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| XL184 (Cabozantinib) | — | 90/214 (42.1%) | 213/214 (99.5%) |
| Placebo | — | 25/109 (22.9%) | 102/109 (93.6%) |
| Event | XL184 (Cabozantinib) | Placebo |
|---|---|---|
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/214 | 6/109 |
| PneumoniaInfections and infestations | 7/214 | 3/109 |
| Mucosal inflammationGeneral disorders | 6/214 | 0/109 |
| HypocalcaemiaMetabolism and nutrition disorders | 6/214 | 0/109 |
| DysphagiaGastrointestinal disorders | 5/214 | 2/109 |
| DehydrationMetabolism and nutrition disorders | 5/214 | 1/109 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 5/214 | 0/109 |
| HypertensionVascular disorders | 5/214 | 0/109 |
| VomitingGastrointestinal disorders | 4/214 | 1/109 |
| FatigueGeneral disorders | 4/214 | 1/109 |
| Event | XL184 (Cabozantinib) | Placebo |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 135/214 | 36/109 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 105/214 | 2/109 |
| Weight decreasedInvestigations | 102/214 | 11/109 |
| Decreased appetiteMetabolism and nutrition disorders | 98/214 | 17/109 |
| NauseaGastrointestinal disorders | 92/214 | 23/109 |
| FatigueGeneral disorders | 86/214 | 31/109 |
| DysgeusiaNervous system disorders | 73/214 | 6/109 |
| Hair colour changesSkin and subcutaneous tissue disorders | 72/214 | 1/109 |
| StomatitisGastrointestinal disorders | 62/214 | 3/109 |
| HypertensionVascular disorders | 62/214 | 4/109 |
| Age, Categorical(Participants) | XL184 (Cabozantinib) | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 172 | 86 | 258 |
| >=65 years | 47 | 25 | 72 |
| Age, Continuous(years) | XL184 (Cabozantinib) | Placebo | Total |
|---|---|---|---|
| Mean | 54.4 ± 13.33 | 53.8 ± 13.39 | 54.2 ± 13.33 |
| Sex: Female, Male(Participants) | XL184 (Cabozantinib) | Placebo | Total |
|---|---|---|---|
| Female | 68 | 41 | 109 |
| Male | 151 | 70 | 221 |
| Region of Enrollment(participants) | XL184 (Cabozantinib) | Placebo | Total |
|---|---|---|---|
| Austria | 8 | 1 | 9 |
| Belgium | 7 | 5 | 12 |
| Brazil | 4 | 3 | 7 |
| Canada | 6 | 2 | 8 |
| Chile | 0 | 1 | 1 |
| Denmark | 1 | 0 | 1 |
| France | 25 | 5 | 30 |
| Germany | 15 | 10 | 25 |
| Greece | 1 | 2 | 3 |
| Portugal | 0 | 1 | 1 |
| India | 5 | 1 | 6 |
| Israel | 5 | 4 | 9 |
| Italy | 28 | 14 | 42 |
| Korea, Republic of | 3 | 4 | 7 |
| Netherlands | 5 | 3 | 8 |
| Peru | 1 | 0 | 1 |
| Poland | 12 | 3 | 15 |
| Russian Federation | 8 | 5 | 13 |
| Spain | 5 | 3 | 8 |
| Switzerland | 1 | 0 | 1 |
| Sweden | 6 | 4 | 10 |
| United Kingdom | 10 | 9 | 19 |
| United States | 63 | 31 | 94 |
Showing the first 100 of 114 sites across 24 countries. Choose a country and city above to see the rest.
The record gives a start of Jun 2008, a primary completion of Oct 2011 and a completion of Sep 2020. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2014, 2 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cabozantinib